Unlocking the Value of R&D: Managing the Risks

Martyn Postle;Duncan Pass;

Publication

Article

June 15, 2002

BioPharm International

BioPharm International-06-01-2002

Volume15

Issue 6

Unlocking the Value of R&D: Managing the Risks

Author(s):

Martyn Postle,Duncan Pass

by Duncan Pass, and Martyn Postle, Cambridge Pharma Consultancy How does big pharma look at your biotech company as a potential partner? This often depends on how it looks at its own research and development investments ? and how it presents them to shareholders. This insider's look at biotech-pharma collaboration shows you the other side of the equation.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Negotiating and Structuring Strategic Alliances

Finding Funding in Biotechnology: Keeping the Companies Alive

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

Unlocking the Value of R&D: Managing the Risks

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!